- cafead   May 14, 2024 at 11:32: AM
via US-based biotechnology company Kodiak Sciences has dosed the first subjects with diabetic retinopathy (DR) in its Phase III GLOW2 clinical trial of tarcocimab tedromer.
The randomised, multi-centre trial will assess the efficacy and safety of tarcocimab tedromer in treatment-naïve DR patients.
article source
The randomised, multi-centre trial will assess the efficacy and safety of tarcocimab tedromer in treatment-naïve DR patients.
article source